{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:51:28Z","timestamp":1778853088849,"version":"3.51.4"},"reference-count":40,"publisher":"Portland Press Ltd.","issue":"5","license":[{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We aim to determine whether nebivolol has a better effect on endothelial dysfunction compared with other \u03b2-blockers or other classes of antihypertensive drugs. Searches of the PubMed, Embase etc. were performed to analyze all the randomized controlled trials using nebivolol to treat essential hypertension. The primary end points included a measurement of peripheral endothelial function by brachial flow mediated vasodilatation (FMD) or forearm blood flow (FBF). A random-effect model was used to perform the meta-analysis when the studies showed significant heterogeneity, otherwise a descriptive analysis was conducted. Ten studies (689 patients) were included in qualitative analysis, four of which were included in quantitative synthesis. Meta-analysis showed that the changed FMD value before and after treatment with nebivolol was not statistically different from those treated with other \u03b2-blockers [mean difference = 1.12, 95% confidence interval (CI): \u22120.56, 2.81, P=0.19]. Descriptive analysis indicated that nebivolol did not have a better endothelium-protective effect than other classes of antihypertensive drugs including olmesartan and perindopril. Nebivolol is not a unique endothelial function-protective agent distinguished from other \u03b2-blockers or other classes of antihypertensive drugs. Reversal of endothelial dysfunction is a key point in the prevention and therapy of essential hypertension.<\/jats:p>","DOI":"10.1042\/bsr20200436","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T10:28:57Z","timestamp":1588069737000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension"],"prefix":"10.1042","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0373-446X","authenticated-orcid":false,"given":"Bingwei","family":"Li","sequence":"first","affiliation":[{"name":"Institute of Microcirculation, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing 100005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuju","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Microcirculation, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing 100005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6837-8443","authenticated-orcid":false,"given":"Honggang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Microcirculation, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing 100005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Microcirculation, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing 100005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruijuan","family":"Xiu","sequence":"additional","affiliation":[{"name":"Institute of Microcirculation, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing 100005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"2021111620101296600_B1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJM199007053230105","article-title":"Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension","volume":"323","author":"Panza","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"2021111620101296600_B2","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1161\/HYPERTENSIONAHA.115.06979","article-title":"Chronic nebivolol treatment suppresses endothelin-1-mediated vasoconstrictor tone in adults with elevated blood pressure","volume":"67","author":"Diehl","year":"2016","journal-title":"Hypertension"},{"key":"2021111620101296600_B3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1161\/HYPERTENSIONAHA.116.08994","article-title":"Dose-response association between physical activity and incident hypertension: a systematic review and meta-analysis of cohort studies","volume":"69","author":"Liu","year":"2017","journal-title":"Hypertension"},{"key":"2021111620101296600_B4","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1097\/HJH.0000000000000965","article-title":"Endothelial dysfunction in human essential hypertension","volume":"34","author":"Mordi","year":"2016","journal-title":"J. Hypertens."},{"key":"2021111620101296600_B5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1748-1716.2009.01964.x","article-title":"Endothelial dysfunction and vascular disease","volume":"196","author":"Vanhoutte","year":"2009","journal-title":"Acta Physiol. (Oxf.)"},{"key":"2021111620101296600_B6","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1097\/HJH.0000000000001001","article-title":"Endothelial dysfunction in hypertension: achievements and open questions","volume":"34","author":"Taddei","year":"2016","journal-title":"J. Hypertens."},{"key":"2021111620101296600_B7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1161\/01.CIR.104.2.191","article-title":"Prognostic significance of endothelial dysfunction in hypertensive patients","volume":"104","author":"Perticone","year":"2001","journal-title":"Circulation"},{"key":"2021111620101296600_B8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0735-1097(02)01976-9","article-title":"Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women","volume":"40","author":"Modena","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111620101296600_B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11906-015-0596-3","article-title":"Clinical significance of endothelial dysfunction in essential hypertension","volume":"17","author":"Gkaliagkousi","year":"2015","journal-title":"Curr. Hypertens. Rep."},{"key":"2021111620101296600_B10","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/0140-6736(92)93147-F","article-title":"Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis","volume":"340","author":"Celermajer","year":"1992","journal-title":"Lancet"},{"key":"2021111620101296600_B11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.5152\/akd.2014.4793","article-title":"Effect of antihypertensive therapy on endothelial markers in newly diagnosed stage 1 hypertension: a randomized single-centre study","volume":"14","author":"Sendur","year":"2014","journal-title":"Anadolu Kardiyol. Derg."},{"key":"2021111620101296600_B12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10554-010-9616-1","article-title":"Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis","volume":"26","author":"Inaba","year":"2010","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"2021111620101296600_B13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/jch.12649","article-title":"Nitric oxide contributes to vasomotor tone in hypertensive african americans treated with nebivolol and metoprolol","volume":"18","author":"Neuman","year":"2016","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"2021111620101296600_B14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1475-097X.2008.00852.x","article-title":"Effect of nebivolol on blood oxygen transport indices and endothelial dysfunction in patients with arterial hypertension","volume":"29","author":"Pronko","year":"2009","journal-title":"Clin. Physiol. Funct. Imaging"},{"key":"2021111620101296600_B15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jacc.2005.04.040","article-title":"Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension","volume":"46","author":"Perticone","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111620101296600_B16","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1097\/HJH.0b013e328356766f","article-title":"Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats","volume":"30","author":"Varagic","year":"2012","journal-title":"J. Hypertens."},{"key":"2021111620101296600_B17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ejvs.2013.11.003","article-title":"The effect of different beta-blockers on vascular graft nitric oxide levels: comparison of nebivolol versus metoprolol","volume":"47","author":"Bayar","year":"2014","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"2021111620101296600_B18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jacc.2010.09.037","article-title":"Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional beta1-blockade","volume":"57","author":"Sorrentino","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111620101296600_B19","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2021111620101296600_B20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1742-7843.2012.00911.x","article-title":"Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension","volume":"111","author":"Zepeda","year":"2012","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"2021111620101296600_B21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1161\/HYPERTENSIONAHA.110.169169","article-title":"beta-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial","volume":"58","author":"Espinola-Klein","year":"2011","journal-title":"Hypertension"},{"key":"2021111620101296600_B22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.artres.2010.10.111","article-title":"The brachial artery endothelial function under the influence of vasoactive antihypertensive treatment","volume":"4","author":"Fedorishina","year":"2010","journal-title":"Artery Res."},{"key":"2021111620101296600_B23","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/ajh.2008.260","article-title":"Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients","volume":"21","author":"Pasini","year":"2008","journal-title":"Am. J. Hypertens."},{"key":"2021111620101296600_B24","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1161\/01.HYP.0000070956.57418.22","article-title":"Different effect of antihypertensive drugs on conduit artery endothelial function","volume":"41","author":"Ghiadoni","year":"2003","journal-title":"Hypertension"},{"key":"2021111620101296600_B25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1161\/hc3001.094207","article-title":"Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study","volume":"104","author":"Tzemos","year":"2001","journal-title":"Circulation"},{"key":"2021111620101296600_B26","first-page":"45","article-title":"Effects of nebivolol versus bisoprolol on endothelial function in hypertensive patients","volume":"14","author":"Simova","year":"2009","journal-title":"Exp. Clin. Cardiol."},{"key":"2021111620101296600_B27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1042\/cs0940601","article-title":"Acute hypertension impairs endothelium-dependent vasodilation","volume":"94","author":"Millgard","year":"1998","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021111620101296600_B28","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1172\/JCI200524806","article-title":"In hypertension, the kidney is not always the heart of the matter","volume":"115","author":"Mendelsohn","year":"2005","journal-title":"J. Clin. Invest."},{"key":"2021111620101296600_B29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.113.004940","article-title":"Enhanced expression of \u03b23-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase","volume":"129","author":"Belge","year":"2014","journal-title":"Circulation"},{"key":"2021111620101296600_B30","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/sj.bjp.0705983","article-title":"Mechanisms of beta 3-adrenoceptor-induced eNOS activation in right atrial and left ventricular human myocardium","volume":"143","author":"Brixius","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"2021111620101296600_B31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/cvr\/cvw056","article-title":"Cardiac salvage by tweaking with beta-3-adrenergic receptors","volume":"111","author":"Balligand","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"2021111620101296600_B32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1042\/CS20100476","article-title":"Aging and vascular endothelial function in humans","volume":"120","author":"Seals","year":"2011","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021111620101296600_B33","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1365-2710.2003.00477.x","article-title":"A comparison of the beta1-selectivity of three beta1-selective beta-blockers","volume":"28","author":"Nuttall","year":"2003","journal-title":"J. Clin. Pharm. Ther."},{"key":"2021111620101296600_B34","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00005344-200112003-00003","article-title":"Nebivolol: endothelium-mediated vasodilating effect","volume":"38","author":"Ritter","year":"2001","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2021111620101296600_B35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/01.hjh.0000160216.86597.ff","article-title":"Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation","volume":"23","author":"Fratta Pasini","year":"2005","journal-title":"J. Hypertens."},{"key":"2021111620101296600_B36","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/01.CIR.94.6.1298","article-title":"Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients","volume":"94","author":"Taddei","year":"1996","journal-title":"Circulation"},{"key":"2021111620101296600_B37","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1161\/01.CIR.0000112565.60887.1E","article-title":"Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study","volume":"109","author":"Benjamin","year":"2004","journal-title":"Circulation"},{"key":"2021111620101296600_B38","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jacc.2004.07.027","article-title":"Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women","volume":"44","author":"Rossi","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111620101296600_B39","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1172\/JCI70025","article-title":"Disruption of vascular Ca2+-activated chloride currents lowers blood pressure","volume":"124","author":"Heinze","year":"2014","journal-title":"J. Clin. Invest."},{"key":"2021111620101296600_B40","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1161\/CIRCULATIONAHA.117.033383","article-title":"Endothelial C-type natriuretic peptide acts on pericytes to regulate microcirculatory flow and blood pressure","volume":"138","author":"Spiranec","year":"2018","journal-title":"Circulation"}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20200436\/877856\/bsr-2020-0436.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20200436\/877856\/bsr-2020-0436.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:46:11Z","timestamp":1637095571000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/40\/5\/BSR20200436\/222793\/Effects-of-nebivolol-versus-other-antihypertensive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,29]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20200436","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,5]]},"article-number":"BSR20200436"}}